516-35-8
516-35-8
Chemical Structure
Taurochenodeoxycholic acid
Synonym(s): 12-Deoxycholyltaurine
- CAS No.: 516-35-8
- Formula:C26H45NO6S
- Molecular Weight:499.70
IUPAC Name: 2-((R)-4-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid
InChIKey: BHTRKEVKTKCXOH-BJLOMENOSA-N
SMILES: C[C@@]1([C@@]2([H])[C@H](C)CCC(NCCS(=O)(O)=O)=O)[C@](CC2)([H])[C@@]([C@@H](C[C@]3([H])C[C@H](O)CC4)O)([H])[C@]([C@]34C)([H])CC1
Biological Activity: Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Taurochenodeoxycholic acid | 99.90% | Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taurochenodeoxycholic acid (Standard) | 99.67% | Taurochenodeoxycholic acid (Standard) is the analytical standard of Taurochenodeoxycholic acid. This product is intended for research and analytical applications. Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taurochenodeoxycholic acid-d4 | Taurochenodeoxycholic acid-d4 (TCDCA-d4) is the deuterium labeled Taurochenodeoxycholic acid. Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taurochenodeoxycholic acid-d4 sodium | 99% | Taurochenodeoxycholic acid-d4 (sodium) is the deuterium labeled Taurochenodeoxycholic acid. Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taurolithocholic acid | 98.38% | Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis (Ferroptosis), viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taurolithocholic acid-d4 sodium | 99.4% | Taurolithocholic acid-d4 (sodium) is the deuterium labeled Taurolithocholic acid (sodium salt). Taurolithocholic acid sodium is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taurolithocholic acid-d4 | 98.36% | Taurolithocholic acid-d4 is deuterium labeled Taurolithocholic acid. Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taurohyodeoxycholic acid | 99.73% | Taurohyodeoxycholic acid is an orally active 6 alpha-hydroxylated bile acid. Taurohyodeoxycholic acid decreases colonic MPO activity, TNF-α, lL-6 serum levels and the expression of COX-2. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Taurohyodeoxycholic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice. Taurohyodeoxycholic acid prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats. Taurohyodeoxycholic acid can be used for the study of nonalcoholic fatty liver disease (NAFLD), colitis and biliary fistula. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taurohyocholic acid | 99.89% | Taurohyocholic acid is a taurine-conjugated hyocholic acid. Taurohyocholic acid is predictor of the efficacy of tyrosine kinase inhibitors combined withPD-1 inhibitors in hepatocellular carcinoma (HCC). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tauro-obeticholic acid | 98.2% | Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tauroursodeoxycholate sodium (Standard) | 97.91% | Tauroursodeoxycholate (sodium) (Standard) is the analytical standard of Tauroursodeoxycholate (sodium). This product is intended for research and analytical applications. Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tauroursodeoxycholate-d4 sodium | 99.34% | Tauroursodeoxycholate-d4 (sodium) is the deuterium labeled Tauroursodeoxycholate sodium. Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tauroursodeoxycholate dihydrate (Standard) | ≥98% | Tauroursodeoxycholate (dihydrate) (Standard) is the analytical standard of Tauroursodeoxycholate (dihydrate). This product is intended for research and analytical applications. Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tauroursodeoxycholate (Standard) | ≥98% | Tauroursodeoxycholate (Standard) is the analytical standard of Tauroursodeoxycholate. This product is intended for research and analytical applications. Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tauroursodeoxycholate-d4 | 99.70% | Tauroursodeoxycholate-d4 is deuterium labeled Tauroursodeoxycholate. Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taurocholic acid | 99.83% | Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taurocholic acid-d4 sodium | 99.58% | Taurocholic acid-d4 (sodium) is the deuterium labeled Taurocholic acid. Taurocholic acid (N-Choloyltaurine) is a bile acid involved in the emulsification of fats. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taurocholic acid-d4 | 99.73% | Taurocholic acid-d4 is deuterium labeled Taurocholic acid. Taurocholic acid (N-Choloyltaurine) is a bile acid involved in the emulsification of fats. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taurodeoxycholic acid-d4-1 sodium | 99.9% | Taurodeoxycholic acid-d4 (Taurodeoxycholate-d4-1) sodium is the deuterium labeled Taurodeoxycholic acid sodium. Taurodeoxycholate sodium salt is a bile salt-related anionic detergent. Taurodeoxycholic acid is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholic acid is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholic acid (TDCA) exhibits anti-inflammatory and neuroprotective effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycoursodeoxycholic acid-d4 | 99.78% | Glycoursodeoxycholic acid-d4 (Ursodeoxycholylglycine-d4) is the deuterium labeled Glycoursodeoxycholic acid. Glycoursodeoxycholic acid, a acyl glycine and a bile acid-glycine conjugate, is a metabolite of ursodeoxycholic acid. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taurochenodeoxycholic acid sodium (Standard) | 99.90% | Taurochenodeoxycholic acid (sodium) (Standard) is the analytical standard of Taurochenodeoxycholic acid (sodium). This product is intended for research and analytical applications. Taurochenodeoxycholic acid (12-Deoxycholyltaurine) sodium is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid sodium induces apoptosis and shows obvious anti-inflammatory and immune regulation properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycochenodeoxycholic acid-d4 | 99.95% | Glycochenodeoxycholic acid-d4 is the deuterium labeled Glycochenodeoxycholic acid. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a bile acid formed in the liver from chenodeoxycholate and glycine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) induces hepatocyte apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tauro-β-muricholic acid | 99.91% | Tauro-β-muricholic acid (TβMCA) is an orally active trihydroxylated bile acid and a competitive, reversible FXR antagonist (IC50=40 μM). Tauro-β-muricholic acid inhibits bile acid-induced hepatocyte apoptosis by maintaining mitochondrial membrane potential, while simultaneously inhibiting intestinal FXR signaling, affecting bile acid synthesis, hepatic lipid metabolism, and insulin sensitivity. Accumulation of tauro-β-muricholic acid disrupts metabolic homeostasis, promoting cancer stem cell proliferation and tumor progression. The mechanisms of tauro-β-muricholic acid involve two aspects: first, inhibiting the translocation of the pro-apoptotic protein Bax to mitochondria and maintaining mitochondrial membrane potential (MMP); and second, blocking the FXR signaling pathway to regulate bile acid metabolism, reduce serum ceramide production, and downregulate the hepatic SREBP1C/CIDEA pathway. Tauro-β-muricholic acid possesses anti-hepatocyte apoptosis, bile acid homeostasis regulation, and liver fat accumulation reduction properties, and also functions as a biomarker, making it useful in the study of diseases such as bile acid metabolism disorders, non-alcoholic fatty liver disease, colorectal cancer, and liver fibrosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wang X, et al. Taurochenodeoxycholic acid induces NR8383 cells apoptosis via PKC/JNK-dependent pathway. Eur J Pharmacol. 2016 Sep 5;786:109-15. [Content Brief]
- [2]. Zhou C, et al. The effects of taurochenodeoxycholic acid in preventing pulmonary fibrosis in mice. Pak J Pharm Sci. 2013 Jul;26(4):761-5. [Content Brief]
